Undetectable MRD and Extended PFS More Common with MRD-guided Ibrutinib-Venetoclax than with Ibrutinib Alone or FCR Regimen Among Patients with CLL By Ogkologos - October 13, 2025 243 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FLAIR study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Dr Ian Walker on Smoking: ‘A political no-brainer’ March 24, 2023 How Living in Service to Others Helped Me Cope During Cancer March 9, 2023 Five Questions With…Jim. April 28, 2022 Patient Guide in Hepatocellular Carcinoma Now Available Also in German December 16, 2025 Load more HOT NEWS Foodie Fridays: Farmer’s Market Finds Preclinical Study May Have Found New Treatment Option for Triple-Negative Breast... Brentuximab Approved for Initial Treatment of Advanced Hodgkin Lymphoma Nivolumab Added to Cisplatin and Radiotherapy Improves DFS in Patients with...
